Co-treatment substantially reduced the diabetes-induced upregulation of Slc2a2, but not Slc5a1 and Slc5a2, mRNA levels when compared to all other diabetic arms (Fig. 4a–c). The gene discussed is SLC5A2; the disease is diabetes mellitus.